I agree with the limits of BA with resveratrol. I think pterostilbene is better. Great info on sulforaphane, I didn’t know about the sirtuin connection. I eat broc sprouts and the freeze dried ones. Akshay likes a pill, sulforadex, but I can’t find it.

Set forth below is information concerning the directors, senior management and executive officers of the Company as of February 28, 2019, the latest practicable date for inclusion in this annual report. The business address for each of our directors, senior management and corporate officers is c/o Galmed Pharmaceuticals Ltd., 16 Tiomkin St., Tel Aviv 6578317, Israel.

Togawa, H. et al. Epithelial-to-mesenchymal transition in cyst lining epithelial cells in an orthologous PCK rat model of autosomal-recessive polycystic kidney disease. American journal of physiology Renal physiology. 300, F511–520 (2011).

Moreover, capital gains derived by an individual shareholder who is a dealer or trader in securities, or to whom such income is otherwise taxable as ordinary business income, are taxed in Israel at their marginal rates applicable to business income (up to 50% in 2017 and 2018, including Excess Tax as detailed below). 

If we receive marketing approval for Aramchol, sales will be limited unless the product achieves broad market acceptance.

        In March 2019, we announced pre-clinical data for the extended release, or XR, formulation of zilucoplan, in which a single subcutaneous dose achieved greater than one week of target drug concentrations in non-human primates, supporting once weekly or less frequent dosing. We anticipate the XR program entering human clinical studies in the first half of 2020.

Derma Sciences, Inc. (NasdaqCM:DSCI) is a medical technology company focused on three segments of the wound care marketplace, traditional dressings, advanced wound care dressings and pharmaceutical wound care products. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 patients with leg ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudates, and BIOGUARD® for infection prevention. As noted above, Derma Sciences expects to complete the efficacy portion of its Phase 2 clinical study with DSC127, a novel pharmaceutical for accelerated wound healing and scar reduction, by the end of 2010.

Our general and administrative expenses amounted to approximately $3.8 million for the year ended December 31, 2017, representing an increase of approximately $0.7 million, or 23%, compared to approximately $3.1 million for the year ended December 31, 2016. The increase primarily resulted from an increase in salaries and benefits expenses of approximately $0.6 million as well as an increase in investor relations and business development expenses of approximately $0.2 million. 

        The Company’s share-based compensation programs grant awards which may include stock options, restricted stock awards (RSAs), restricted stock units (RSUs), and other stock-based awards.

Ocarino, N. M. et al. Osteogenic differentiation of mesenchymal stem cells from osteopenic rats subjected to physical activity with and without nitric oxide synthase inhibition. Nitric Oxide 19, 320–325 (2008).

Böger, R. H., Maas, R., Schulze, F. & Schwedhelm, E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality—an update on patient populations with a wide range of cardiovascular risk. Pharmacological Research 60, 481–487 (2009).

There’s a chemical contamination story in the generic drug industry that just isn’t going away. Late last summer, some lots of valsartan were recalled due to detection of N-nitrosodimethylamine (NDMA), and the problem has just continued since then. We’ll get into the chemistry of this problem in a minute, but first off, looking at this situation in detail tells you a lot about the generic drug business. A key point is that there are often just a few sources of actual API (active pharmaceutical ingredient). Other companies buy this material and formulate it into capsules, tablets, etc., and then still more companies repackage these. The patented drug world, by contrast, is a lot easier to follow, since while a drug is under patent there’s only one company that’s authorized to market it. They may well have several suppliers for different starting materials or for different steps of their synthesis, but it’s at least one defined route managed by one company.